Skip to main content


  • Meeting abstract
  • Open Access

The trafficking of GPR55 is regulated by the G protein-coupled receptor-associated sorting protein 1

  • 1,
  • 1,
  • 1,
  • 2,
  • 2 and
  • 1Email author
BMC Pharmacology201010 (Suppl 1) :A1

  • Published:


  • HEK293 Cell
  • Induce Weight Loss
  • Degradative Pathway
  • Analgesic Tolerance
  • Tangible Evidence


The G protein-coupled receptor 55 (GPR55) has recently been suggested to be responsible for those cannabinoid responses that could not be attributed to either the cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor. Several potent GPR55 agonists were identified, such as lysophosphatidylinositol (LPI) and synthetic cannabinoids: One of these is rimonabant (SR141716A), which until that date was known to be an inverse agonist/antagonist on the CB1 receptor. Rimonabant has further attracted attention since it was marketed to induce weight loss and reduce smoking. However, due to severe side effects after prolonged use, such as the development of anxiety and depression, rimonabant was taken off the market. Generally, the activity of GPCRs is coordinated by receptor signaling, receptor desensitization and receptor resensitization. One regulatory mechanism to guarantee appropriate GPCR expression levels in physiological conditions is that of downregulating GPCRs via the G protein-coupled receptor-associated sorting protein 1 (GASP-1), thus leading to an attenuation of cellular signaling events. GASP-1 was originally found to target δ opioid receptors to lysosomes and, hence, to be a degradative pathway. It was shown that GASP-1 is a key determinant in the development of analgesic tolerance to cannabinoids via its role in facilitating downregulation of the CB1 receptor.


All experiments were performed using Human Embryonic Kidney (HEK293) cells and HEK293 cells stably expressing FLAG-tagged GPR55. Knock-down of endogenous GASP-1 levels were induced by infection with Lenti-shGASP-1 (shGASP-1) or Lenti-shScrambled (shScr) virus. The post-endocytic trafficking of GPR55 and its regulation by GASP-1 was elucidated by means of immunocytochemistry and biotinylation degradation experiments.


By a variety of approaches, we demonstrated that GPR55 directly interacts with GASP-1 and is targeted to the degradative pathway via GASP-1 in a recombinant HEK293 cell model. For instance, knockdown of endogenous GASP-1 in HEK293 cells using shRNA silencing changes the trafficking properties of GPR55.


This work provides tangible evidence that GPR55 is degraded after prolonged agonist stimulation and this mechanism is regulated by the G protein-coupled receptor-associated sorting protein 1.

Authors’ Affiliations

Institute of Experimental and Clinical Pharmacology, Medical University of Graz, 8010 Graz, Austria
Ernest Gallo Clinic and Research Center, University of California, San Francisco, CA 94608, USA


© Waldhoer et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.